摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[(2R,3S,4S,5S,6R)-6-[[(8S,11S,12R,18S)-12-[(2R,3S,4R,5S)-3,4-dihydroxy-6,6-dimethyl-5-(2-methylpropanoyloxy)oxan-2-yl]oxy-11-ethyl-8-hydroxy-18-(1-hydroxyethyl)-9,13,15-trimethyl-2-oxo-1-oxacyclooctadeca-3,5,9,13,15-pentaen-3-yl]methoxy]-4-hydroxy-5-methoxy-2-methyloxan-3-yl] 3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate

中文名称
——
中文别名
——
英文名称
[(2R,3S,4S,5S,6R)-6-[[(8S,11S,12R,18S)-12-[(2R,3S,4R,5S)-3,4-dihydroxy-6,6-dimethyl-5-(2-methylpropanoyloxy)oxan-2-yl]oxy-11-ethyl-8-hydroxy-18-(1-hydroxyethyl)-9,13,15-trimethyl-2-oxo-1-oxacyclooctadeca-3,5,9,13,15-pentaen-3-yl]methoxy]-4-hydroxy-5-methoxy-2-methyloxan-3-yl] 3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate
英文别名
——
[(2R,3S,4S,5S,6R)-6-[[(8S,11S,12R,18S)-12-[(2R,3S,4R,5S)-3,4-dihydroxy-6,6-dimethyl-5-(2-methylpropanoyloxy)oxan-2-yl]oxy-11-ethyl-8-hydroxy-18-(1-hydroxyethyl)-9,13,15-trimethyl-2-oxo-1-oxacyclooctadeca-3,5,9,13,15-pentaen-3-yl]methoxy]-4-hydroxy-5-methoxy-2-methyloxan-3-yl] 3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate化学式
CAS
——
化学式
C52H74Cl2O18
mdl
——
分子量
1058.0
InChiKey
ZVGNESXIJDCBKN-WVQSPTIHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.4
  • 重原子数:
    72
  • 可旋转键数:
    15
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.63
  • 拓扑面积:
    267
  • 氢给体数:
    7
  • 氢受体数:
    18

文献信息

  • TIACUMICIN DERIVATIVES AND THEIR USE AS ANTIBIOTICS
    申请人:Universität Zürich
    公开号:EP3508492A1
    公开(公告)日:2019-07-10
    The invention relates to a compound according to formula (1) wherein R1 to R4 and X are independently from each other a small functional group and R5 is -OH, or -O-Ln-Rap-Rbq-Lt-Rar-Rbs-Re, -O-Ln-Rbq-Rd-Lt-Rbs-Re with L being an alkyl linker, Ra being carbonyl, carboxyl or carboxamide, Rb being a cyclic moiety, Rd being a polyether linker and Re being a small functional end group, fluorescent dye or antibiotic with the proviso that the compound is not fidaxomicin. Furthermore, the invention relates to the use of the compound in the treatment of disease and the use in treating infections and/or bacterial infections caused by drug resistant bacteria.
    该发明涉及一种符合以下式(1)的化合物,其中R1至R4和X彼此独立地是小的功能基团,R5是-OH,或者-O-Ln-Rap-Rbq-Lt-Rar-Rbs-Re,-O-Ln-Rbq-Rd-Lt-Rbs-Re,其中L是烷基连接物,Ra是酰基,羧基或羧酰胺,Rb是环状基团,Rd是聚醚连接物,Re是小的功能末端基团,荧光染料或抗生素,但该化合物不是fidaxomicin。此外,该发明涉及该化合物在治疗疾病中的应用,以及在治疗由耐药细菌引起的感染和/或细菌感染中的应用。
  • COMPOSITION OF TIACUMICIN COMPOUNDS
    申请人:Astellas Pharma Europe Ltd.
    公开号:EP2945613B1
    公开(公告)日:2018-10-10
  • TREATMENT REGIMEN FOR TIACUMICIN COMPOUND
    申请人:Astellas Pharma Europe Ltd.
    公开号:EP3139932B1
    公开(公告)日:2018-08-01
  • US9808530B2
    申请人:——
    公开号:US9808530B2
    公开(公告)日:2017-11-07
查看更多